Conversely, the benefit of the combination of an anti-PD-1/anti-PD-L1 antibody with a TKI has been proved for the first time in a phase III trial enrolling mostly Asian patients with unresectable HCC. Here, CD274 is linked to hepatocellular carcinoma.